Analyst Ratings

FDA Clears First Broadly RAS‑Targeting Pill for Advanced Pancreatic Cancer

Roughly doubling median survival in a Phase 3 trial, the oral drug introduces a new treatment option that will prompt rapid clinical rollout, toxicity planning, and further studies.